BRAINTEASER project aims to support patients with amyotrophic lateral sclerosis and multiple sclerosis and their clinicians. “Amyotrophic Lateral Sclerosis” campaign wants to bring attention to this condition and analyse the variables that might affect its progression. In “The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis” M. Kelly et al. report the results of an exploratory, non-controlled, nondrug study that aimed to objectively monitor ALS patients at home, to explore novel disease progression markers.
Save the Date: BRAINTEASER final event to take place at ENCALS 2025 in Turin
As the BRAINTEASER project approaches its conclusion, its final conference will be held on 3 June...
